Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.

B. Riley Financial and its subsidiaries provide investment banking and financial services to corporate, institutional and high net worth clients, and asset disposition, valuation and appraisal and capital advisory services to a range of retail, wholesale and industrial clients, as well as lenders, capital providers, private equity investors and professional services firms throughout the U.S., Australia, Canada, and Europe. The company also provides consumer Internet access and related subscription services. The company's operating segments are: Capital Markets, Auction and Liquidation, Valuation and Appraisal, and Principal Investments - United Online and magicJack.

Bridge Bancorp is a bank holding company. Through its subsidiary, the company is engaged in commercial and consumer banking business, including accepting time, savings and demand deposits from the consumers, businesses and local municipalities in its market area. The company also provides the Certificate of Deposit Account Registry Service and Insured Cash Sweep programs. In addition, the company provides merchant credit and debit card processing, automated teller machines, cash management services, lockbox processing, online banking services, remote deposit capture, safe deposit boxes, and individual retirement accounts as well as investment services through Bridge Financial Services LLC.

Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

Citizens Financial Services is a bank holding company for First Citizens Community Bank (the Bank). The company is primarily engaged in the ownership and management of the Bank and the Bank's wholly-owned insurance agency subsidiary, First Citizens Insurance Agency, Inc. The Bank is engaged in a range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other financial services.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is on the development of its key product candidate, Neutrolin

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

IGM Biosciences is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

LiveXLive Media is a digital media company focused on live entertainment and music services. The company is engaged in the acquisition, distribution and monetization of live music, Internet radio and music-related streaming and video content. Through its service offerings and content platform, the company provides music fans the ability to engage in and listen to live music, digital Internet radio and music streaming services on any connected device and screen 24/7/365, including desk-top, tablets, mobile applications and automobile music play interfaces. The company operates LiveXLive, a live music streaming platforms; Slacker Radio, a streaming music service; and also produces original music-related content.

Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. In patients with metastatic breast cancer, tesetaxel was shown to have single-agent antitumor activity in two multicenter, Phase 2 studies. The company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA.

Tenax Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases. Through its wholly owned subsidiary, Life Newco, Inc. (Life Newco), the company owns a license granting Life Newco a right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.

Whiting Petroleum is an independent oil and gas company engaged in development, production, acquisition, and exploration activities primarily in the Rocky Mountains region of the U.S. The company's existing operations and capital programs are focused on organic drilling activities and on the development of previously acquired properties, while selectively pursuing acquisitions that complement its existing properties. The company principally sells its oil and gas production to end users, marketers and other purchasers that have access to nearby pipeline or rail takeaway. In areas with no access to gathering pipelines, oil is trucked or transported to terminals, market hubs, refineries or storage facilities.

Xerox is a workplace technology company. The company's business areas are: Xerox Services, which offerings in this area are Intelligent Workplace Services and a range of Digital Services that utilize the company's software capabilities in Workflow Automation, Personalization and Communication Software, Content Management Solutions, and Digitization Services; Workplace Solutions, which is made up of two product groups, Entry and Mid-Range, which share common technology, manufacturing and product platforms; and Graphic Communications and Production Solutions, which are designed for customers in the graphic communications, in-plant and production print environments with high-volume printing requirements